Redx Pharma Share Discussion Threads

[the infidel] 27/3/2015 07:20

Gonna move

[mirabeau] 27/3/2015 07:18

BR

Caveat. This thread is for information and monitoring purposes only. I don't intend to buy due to lack of available funds. Moreover I have no idea as to the fundamental value of REDX so people should DTOR

Good luck

[bad robot] 27/3/2015 07:07

Good morning

[bad robot] 26/3/2015 21:14

Brace for IMPACT

IPO !!!!!!!!!!!!!!!!!!!!!!!!!

[bad robot] 26/3/2015 21:14

Description of business:
Redx is an established, income generating drug discovery and development company formed in 2010, with approximately 140 employees across two sites in Liverpool and Alderley Park, Cheshire. The group is focused on the development of proprietary, small molecule therapeutics to address areas of unmet medical need principally in two areas, cancer and infectious disease. Through its rational drug design and smart chemistry capabilities, originally built from its Redox SwitchTM technology, Redx has established an extensive pipeline of proprietary drug candidates, targeting best-in-class performance, which are patent protected and focused on commercially relevant targets. Redx's work has been endorsed by partnerships with global pharmaceutical companies and the NHS. The Company's approach is to focus on improving the characteristics of existing drug classes to create highly differentiated best-in-class new drugs. Over a short period, Redx has already established a portfolio of 13 proprietary, (patent protected) drug programmes. Four programmes have achieved pre-clinical proof of concept, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain and blood cancers, where the Company has demonstrated superior performance to competitor drugs. As part of its business model, Redx seeks partnering and licensing deals at an early stage in its drug development programmes with large and emerging mid-size pharmaceutical companies. These partnerships have the potential to deliver development and sales milestone income to Redx as well as royalties on future sales. To date, Redx has secured five commercial partnerships and collaborations, the most significant being a two year research collaboration and option agreement, signed in August 2014, with AstraZeneca UK Limited.



BRACE FOR IMPACT

Ticker REDX

Our REDX MASCOT

[mirabeau] 26/3/2015 10:12

'Redx is using advances in gene science to develop new personalised medicines to target cancer and infectious diseases and will be using its new funds to develop a third subsidiary that will research immunology-related treatments.

It has also clinched a number of major collaboration contracts, including from the NHS and AstraZeneca, which bode well for the future. The AstraZeneca contract is potentially worth £300m over 20-years if Redx’s research programme hits milestones and other targets.

This cancer-related project is one of 13 research programmes currently being undertaken by Redx. The company expects to achieve turnover of around £8m next year.'

[mirabeau] 26/3/2015 07:17

Venture capitalist Jon Moulton has invested in biotech company RedX Pharma

A Liverpool-based biotech company, backed by venture capitalist Jon Moulton, will float in London on Friday in a sign of life for Britain’s life science industry beyond the southeast.

RedX Pharma is set to raise £15m in its initial public offering on London’s junior Alternative Investment Market and be valued at about £55m. Its shares were priced on Thursday at 85p each. Besides its headquarters on Merseyside, the drug development company also has a research base at Alderley Park in the Cheshire constituency of George Osborne, the UK chancellor.

RedX is at the heart of efforts by regional leaders to keep a strong biotech cluster at the site south of Manchester after AstraZeneca’s decision two years ago to move thousands of research jobs from the park to a new facility in Cambridge.

Neil Murray, RedX chief executive, said the IPO showed that the northwest could successfully compete for life science investment against companies in the “golden triangle” between London, Oxford and Cambridge.

“The northwest is an exciting place to be at the moment,” he said. “AstraZeneca has done a good job ensuring that they leave a real legacy in the region and there is a strong pool of scientific talent and finance.”

Mr Moulton, will increase his investment through the listing and remain the biggest shareholder with 16.8 per cent. AXA Framlington is among the big institutions backing the float.

The private equity veteran recently came under fire from MPs after City Link, the parcel delivery company owned by his Better Capital vehicle, fell into administration on Christmas Eve and put 2,760 jobs at risk.

RedX’s listing adds to tentative signs of revival in UK investor appetite for biotech after fundraisings in the past year — most notably the £200m IPO of Circassia, an Oxford-based anti-allergy specialist.

However, RedX looks set to raise less than the £20m originally targeted and London remains less receptive to the high-risk sector than New York, where the Nasdaq biotech index has more than doubled in the past two years.

Bidhi Bhoma, director of corporate finance at Shore Capital, which acted as adviser and broker for RedX, said there was a “strong pipeline” of life science companies considering floats in London.

RedX, which has received regional development funding from the government, will use the money raised to advance its research and development in areas including cancer and anti-infectives. It plans to increase its workforce from about 150 to 200.

The company has a partnership with AstraZeneca and aims to forge further deals. “Rather than a biotech company focused on one or two therapies we have a range of proprietary assets that can help big pharmaceuticals companies refill their pipelines,” Mr Murray said.

RedX is active in an area called cancer immunotherapy which has emerged as one of the hottest fields of drug development because of its potential to harness the body’s own immune system to fight tumours.

Anti-infectives are also attracting renewed interest as global policy makers push the industry to tackle the problem of antimicrobial resistance. “Large pharma companies are coming back into this area and we want to be in a position to provide them with assets,” Mr Murray said.